137 related articles for article (PubMed ID: 29870646)
1. [Change of therapeutic algorithm in sclerosis multiplex based on two case reports].
Biernacki T; Bencsik K; Kincses ZT; Sandi D; Fricska-Nagy Z; Faragó P; Vécsei L
Ideggyogy Sz; 2017 Nov; 70(11-12):381-387. PubMed ID: 29870646
[TBL] [Abstract][Full Text] [Related]
2. [Alemtuzumab therapy 2017].
Biernacki T; Bencsik K; Sandi D; Vécsei L
Ideggyogy Sz; 2017 Nov; 70(11-12):371-380. PubMed ID: 29870645
[TBL] [Abstract][Full Text] [Related]
3. Autoimmune encephalitis following alemtuzumab treatment of multiple sclerosis.
Giarola B; Massey J; Barnett Y; Rodrigues M; Sutton I
Mult Scler Relat Disord; 2019 Feb; 28():31-33. PubMed ID: 30553166
[TBL] [Abstract][Full Text] [Related]
4. Severe B cell-mediated disease activation despite two cycles of alemtuzumab in a patient with multiple sclerosis.
Hyun JW; Kim Y; Kim G; Kim SH; Kim HJ
Mult Scler; 2019 Dec; 25(14):1942-1945. PubMed ID: 30403365
[TBL] [Abstract][Full Text] [Related]
5. Myasthenia gravis following alemtuzumab therapy for multiple sclerosis.
Midaglia L; Gratacòs M; Caronna E; Raguer N; Sastre-Garriga J; Montalban X; Tintoré M
Neurology; 2018 Sep; 91(13):622-624. PubMed ID: 30143565
[No Abstract] [Full Text] [Related]
6. [Magnetic resonance imaging in the course of alemtuzumab and teriflunomide therapy].
Mike A; Kincses ZT; Vécsei L
Ideggyogy Sz; 2017 Jan; 70(1-2):15-24. PubMed ID: 29870189
[TBL] [Abstract][Full Text] [Related]
7. Neutropenia with fatal outcome in a multiple sclerosis patient 23 days after alemtuzumab infusion.
Yiannopoulou KG; Papadimitriou D; Anastasiou AI; Siakantaris M
Mult Scler Relat Disord; 2018 Jul; 23():15-16. PubMed ID: 29730587
[TBL] [Abstract][Full Text] [Related]
8. Monitoring and management of autoimmunity in multiple sclerosis patients treated with alemtuzumab: practical recommendations.
Devonshire V; Phillips R; Wass H; Da Roza G; Senior P
J Neurol; 2018 Nov; 265(11):2494-2505. PubMed ID: 29525836
[TBL] [Abstract][Full Text] [Related]
9. Multiple sclerosis: structural and functional integrity of the visual system following alemtuzumab therapy.
Wang C; Barton J; Kyle K; Ly L; Barnett Y; Hartung HP; Reddel SW; Beadnall H; Taha M; Klistorner A; Barnett MH
J Neurol Neurosurg Psychiatry; 2021 Dec; 92(12):1319-1324. PubMed ID: 34187865
[TBL] [Abstract][Full Text] [Related]
10. Severe CNS inflammation after discontinuation of natalizumab and start of daclizumab successfully treated with alemtuzumab.
Hümmert MW; Deppe J; Pul R; Wurster U; Schwenkenbecher P; Sühs KW; Bronzlik P; Stangel M; Skripuletz T
Mult Scler Relat Disord; 2018 May; 22():87-89. PubMed ID: 29631243
[TBL] [Abstract][Full Text] [Related]
11. B cell treatments for multiple sclerosis.
McLauchlan D; Robertson NP
J Neurol; 2017 Apr; 264(4):814-816. PubMed ID: 28260119
[No Abstract] [Full Text] [Related]
12. Marked neutropenia: Significant but rare in people with multiple sclerosis after alemtuzumab treatment.
Baker D; Giovannoni G; Schmierer K
Mult Scler Relat Disord; 2017 Nov; 18():181-183. PubMed ID: 29141806
[TBL] [Abstract][Full Text] [Related]
13. A case of acute fulminant multiple sclerosis treated with alemtuzumab.
Gobbin F; Marangi A; Orlandi R; Richelli S; Turatti M; Calabrese M; Forgione A; Alessandrini F; Benedetti MD; Monaco S; Gajofatto A
Mult Scler Relat Disord; 2017 Oct; 17():9-11. PubMed ID: 29055482
[TBL] [Abstract][Full Text] [Related]
14. Early transient asymptomatic neutropenia associated with alemtuzumab treatment in multiple sclerosis: a case report.
Galgani S; Prosperini L; Haggiag S; Tortorella C; Gasperini C
J Neurol; 2018 Sep; 265(9):2152-2153. PubMed ID: 30019085
[No Abstract] [Full Text] [Related]
15. Alemtuzumab and prescription medication use in the MS population.
Chertcoff A; Ng HS; Zhu F; Zhao Y; Kingwell E; Tremlett H
Mult Scler Relat Disord; 2020 Jul; 42():102086. PubMed ID: 32403069
[TBL] [Abstract][Full Text] [Related]
16. Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis.
Arroyo González R; Kita M; Crayton H; Havrdova E; Margolin DH; Lake SL; Giovannoni G;
Mult Scler; 2017 Sep; 23(10):1367-1376. PubMed ID: 27885061
[TBL] [Abstract][Full Text] [Related]
17. [The use of alemtuzumab after non-selective immunosuppression in a patient with highly active rapidly progressive remitting multiple sclerosis].
Popova EV
Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(2. Vyp. 2):116-120. PubMed ID: 31156250
[TBL] [Abstract][Full Text] [Related]
18. Pneumonitis secondary to alemtuzumab in a patient with multiple sclerosis - A non-infectious cause of breathlessness.
Whiteside D; Barth S; Datta A; Trip SA
Mult Scler Relat Disord; 2018 May; 22():139-140. PubMed ID: 29684788
[TBL] [Abstract][Full Text] [Related]
19. Mild COVID-19 infection in a patient with multiple sclerosis and severe depletion of T-lymphocyte subsets due to alemtuzumab.
Guevara C; Villa E; Cifuentes M; Naves R; Grazia J
Mult Scler Relat Disord; 2020 Sep; 44():102314. PubMed ID: 32593959
[No Abstract] [Full Text] [Related]
20. Acquired haemophilia A complicating alemtuzumab therapy for multiple sclerosis.
McCaughan G; Massey J; Sutton I; Curnow J
BMJ Case Rep; 2017 Dec; 2017():. PubMed ID: 29212866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
